1. Scrip
  2. >>Business

Finance Watch: The Curious Case Of Proteostasis' Short Attack

 
• By Mandy Jackson

Proteostasis planned to raise cash this week, but scrapped the offering after an investor that shorted the stock published a scathing report. Also, Arena raised more than $350m in an offering after its positive Phase II etrasimod data, and venture capital flows to biopharma firms with big ideas.

Finance Watch

Public biopharmaceutical companies have had few problems raising significant cash in 2018, but Proteostasis Therapeutics Inc. withdrew a planned offering of 9m shares on March 20 after an investor with a short position in Proteostasis stock launched an attack on the company's credibility.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business